-+ 0.00%
-+ 0.00%
-+ 0.00%

Editas Medicine Reports 58% Mean HBG1/2 Promoter Editing At Five Months Using Single-Dose tLNP Delivery in Non-Human Primates

Benzinga·06/12/2025 07:26:23
Listen to the news
  • Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy.
  • Achievement supports development of a novel, in vivo approach to treating sickle cell disease and beta thalassemia.